CytoMed, Inc.

1352 Middlebury Drive, Westfield, IN 46074

Tel. 941-751-2872Fax. 317-816-1243

 

 

 

W E L L N E S S

on purpose

 

 

 

 

 


August 24, 2011

 

 

Subject: CoQLIFE

 

To Our Dear Customers:

Over the past couple of months we have received some inquiries asking if our CoQLIFE is the oxidized ubiquinone or the reduced ubiquinol; the difference being two hydrogen ions.Our CoQLIFE is ubiquinone.And here are the reasons Dr. Judy prefers to use ubiquinone rather than ubiquinol:

1.      Ubiquinone has been researched for more than 40 years.There are literally 10ís of thousands of studies using ubiquinone.Commercially available ubiquinol is relatively new and has been researched for less than 5 years.There remain several unresolved questions as to its stability, absorption, and safety.

2.      The CoQ10 synthesized in the human body is ubiquinone.It is true that the greater percent of CoQ10 is converted from ubiquinone to ubiquinol to be used by the body cells as a potent antioxidant.(Ubiquinone is used for energy production.)However, in this conversion some essential biochemical changes occur.Ubiquinone is first converted to a semiquinone and then to ubiquinol.When ubiquinol is ingested rather than ubiquinone this important step is bypassed and we really donít yet know what the ramification of skipping this step may be.

3.      Ubiquinol costs three times more than ubiquinone.There are a very small percentage of people worldwide who have a genetic aberration that causes them to be unable to absorb ubiquinone and, for them, ubiquinol appears to be a viable alternative.But the majority of people can absorb CoQ10, when it is properly prepared (single molecules in a lipid carrier).In addition, there is no proof that ubiquinol is absorbed as ubiquinol.In the presence of oxygen, ubiquinol is converted to ubiquinone.There is oxygen in the stomach so when the ubiquinone enters the digestive tract it may very well be converted to ubiquinone.So why pay more for unstable ubiquinol?

4.      Some of you may have heard that the 15 year study using CoQ10 in elderly, more severe Parkinsonís patients had a negative result.In other words they did not prove that CoQ10 ameliorated the debilitating symptoms of Parkinsonís disease.†† However, it was found that when used in younger, less severe cases of Parkinsonís, CoQ10 did have a benefit in that it reduced or eliminated the symptoms.The reason for the failure of the study in elderly patients may be due to the poor quality CoQ10 product used.They used dry powder, crystal CoQ10 and were not able to raise the blood levels to a therapeutic level.To be therapeutic CoQ10 blood levels need to be above 3.5 ug/ml; in this study, using 1600 to 2400 mg of CoQ10, they were not able to raise the blood levels above 3.0 ug/ml.We are currently using 250 mg of CoQLIFE in these types of patients and are able to raise the blood levels above 4.4 ug/ml.We have been advising the NIH sponsors for 10 years that they are using the wrong CoQ10 formulation and therefore are not able to raise the blood levels to an adequate level for treatment of advanced Parkinsonís.

 

Sincerely,

 

____________________

William V. Judy, PhD

President

CytoMed, Inc.

941.751.2872